oncolytic peptide amphipathic peptides that specifically induce cell death in cancer cells - one-skin-os1-peptide LTX-315 is an oncolytic peptide Oncolytic Peptides: A New Frontier in Cancer Therapy

vitality-collagen-peptides The dominant search intent from the provided data is to understand what oncolytic peptides are, how they work, and their potential in cancer treatment. The most important core entities are "oncolytic peptide" and "cancer treatment." Key attributes and high-relevance phrases include inducing cell death, targeting cancer cells, remodeling the tumor microenvironment, and stimulating immune responses. Specific examples like LTX-315 and NF27 are also significant.

Oncolytic peptides are a promising class of therapeutic agents designed to selectively target and destroy cancer cells, offering a novel approach to cancer treatment. These peptides, often derived from natural host defense peptides or antimicrobial peptides, possess the remarkable ability to induce programmed cell death in malignant cells while sparing healthy tissues.作者：J Spicer·2021·被引用次数：71—Theoncolytic peptide LTX-315is a 9-mer peptide designed by structure–activity relationship studies from the host defense peptide lactoferricin (4, 5). It ... Their mechanism of action typically involves disrupting the cell membrane of cancer cells, leading to lysis and subsequent tumor eradication. Beyond direct cell killing, oncolytic peptides also play a crucial role in remodeling the tumor microenvironment and potentiating anticancer immune responses, thereby offering a synergistic approach to combatting cancer.

Mechanisms of Action: How Oncolytic Peptides Work

The therapeutic efficacy of oncolytic peptides stems from their multifaceted mechanisms of action, which can be broadly categorized into direct cell lysis and immunomodulation.

Direct Cell Lysis: A primary mechanism involves the direct interaction of oncolytic peptides with the plasma membrane of cancer cells. Due to differences in membrane composition, such as a higher negative charge or specific lipid concentrations, cancer cells are often more susceptible to peptide-induced damage. The amphipathic nature of many oncolytic peptides allows them to insert into and disrupt the lipid bilayer of cancer cell membranes. This disruption can lead to a rapid loss of membrane integrity, osmotic imbalance, and ultimately, cell death. Some peptides, like LTX-315, have been shown to induce rapid plasma membrane disruption and cell death.

Immunomodulation and Tumor Microenvironment Remodeling: Beyond direct cytotoxicity, oncolytic peptides are potent modulators of the tumor microenvironment and the immune system. Upon inducing cancer cell death, they trigger the release of damage-associated molecular patterns (DAMPs). These DAMPs act as danger signals, alerting the immune system to the presence of cancer.作者：T Tang·2022·被引用次数：23—BackgroundLTX-315 is an oncolytic peptidederiving from bovine lactoferrin, with the ability to induce cancer immunogenic cell death. This process, known as immunogenic cell death (ICD), is crucial for initiating a robust anti-tumor immune response. Oncolytic peptides can promote the infiltration of immune cells, such as T cells, into the tumor and enhance their anti-cancer activity. This synergistic effect, combining direct tumor cell killing with immune system activation, positions oncolytic peptides as a powerful tool in immunotherapy.

Key Examples and Development

The research and development in the field of oncolytic peptides have led to the identification and study of several promising candidates.

LTX-315: This first-in-class oncolytic peptide has been extensively studied for its therapeutic potential. Designed based on structure-activity relationship studies of host defense peptides, LTX-315 has demonstrated the ability to induce cancer cell death through mechanisms involving plasma membrane perturbation and mitochondrial membrane permeabilization. Clinical trials have explored its efficacy, often in combination with other cancer therapies like checkpoint inhibitors, to generate de novo T-cell responses and achieve clinical benefit in patients.

NF27: Another identified oncolytic peptide, NF27, has shown effectiveness in inhibiting tumor growth. It works by inducing immunogenic cancer cell death and eradicating tumors with low toxicity, highlighting the ongoing discovery of novel peptides with enhanced properties.

Hybrid and Modified Peptides: Researchers are also exploring hybrid peptides, such as those created by fusing different peptide sequences, to enhance their anti-cancer activity and targeting capabilities. For instance, hybrid peptides derived from the fusion of known oncolytic peptides and other molecules have shown improved efficacy in targeting specific cancer cells.

Advantages and Future Prospects

Oncolytic peptides offer several advantages in cancer therapy. Their tumor-specific targeting can minimize damage to healthy tissues, leading to reduced side effects compared to traditional chemotherapy. The ability to induce both direct cell death and a robust anti-tumor immune response provides a dual-action therapeutic strategy.作者：BE Haug·2016·被引用次数：123—The potential first in classoncolytic peptidedrug candidate, peptide 5, was discovered through systematic design of 9-mer cationic peptides ... Furthermore, their peptide nature allows for relatively straightforward synthesis and modification, enabling the development of optimized therapeutic agents.

The ongoing research into oncolytic peptides is expanding their potential applicationsJournal of Medicinal Chemistry - ACS Publications. They are being investigated for their efficacy against various cancer types, including those that are therapy-resistant. The development of oncolytic peptide-nanoplatforms further enhances their delivery and therapeutic potential, driving oncoimmune responses. As our understanding of cancer biology and immunology deepens, oncolytic peptides are poised to play an increasingly significant role in the landscape of innovative cancer treatments, aiming for complete and long-lasting remission.